TP53 Mutations and Breast Cancer Outcomes
Author Information
Author(s): EMJJ Berns, IL van Staveren, MP Look, M Smid, JGM Klijn, JA Foekens
Primary Institution: Rotterdam Cancer Institute (Daniel den Hoed Kliniek)/University Hospital Rotterdam
Hypothesis
Mutations in the TP53 gene that directly contact DNA predict poor outcomes in breast cancer patients.
Conclusion
The study found that TP53 mutations, particularly those affecting DNA contact residues, are associated with poorer relapse-free survival in breast cancer patients.
Supporting Evidence
- TP53 mutations were found in 31% of the breast cancer specimens analyzed.
- Missense mutations accounted for 78% of the observed TP53 mutations.
- Patients with TP53 mutations had a median relapse-free survival of 34 months compared to 48 months for those without mutations.
Takeaway
This study shows that changes in a specific gene called TP53 can make breast cancer worse, especially if the changes happen in parts of the gene that touch DNA.
Methodology
The study analyzed TP53 gene mutations in 222 breast cancer specimens using PCR-SSCA and sequencing.
Limitations
The study excluded 45 patients due to unknown tumor characteristics or insufficient follow-up.
Participant Demographics
The study involved 222 female breast cancer patients with a median age of 59 years.
Statistical Information
P-Value
P = 0.02
Confidence Interval
95% CI: 1.1-2.4
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website